Senior Vice President, Finance and Administration · PUMA BIOTECHNOLOGY, INC. (PBYI)

Charles Eyler

A named executive officer of PUMA BIOTECHNOLOGY in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,836,193

Salary $425,198Stock awards $547,650Bonus $187,083

FY2017: $2,927,922

6th of 6 named executive officers at Puma Biotechnology by FY2018 total.

6 named officers on file for PUMA BIOTECHNOLOGY, FY2018

Charles Eyler’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • PBYI’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how PUMA BIOTECHNOLOGY’s whole pay program stands against its peers

  • PUMA BIOTECHNOLOGY’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PBYI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2019 (DEF 14A).

Free

Get Charles Eyler’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Eyler compensation by year

PUMA BIOTECHNOLOGY Summary Compensation Table · all 3 fiscal years held
In US dollars, as PUMA BIOTECHNOLOGY reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$384,244$406,879$425,198
Bonus$207,255$156,648$187,083
Stock awards$570,675$1,606,500$547,650
Option awards$649,195$738,193$657,043
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$14,023$19,702$19,219
Total$1,825,392$2,927,922$1,836,193

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PUMA BIOTECHNOLOGY, INC. DEF 14A filed April 29, 2019, accession 0001193125-19-125238, and prior-year filings. Open the filing on EDGAR.

How this page was built: the PUMA BIOTECHNOLOGY, INC. filed document, accession 0001193125-19-125238. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2019.

$1.8M
$2.9M
$1.8M
FY16
FY17
FY18
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
RSU10,503$213,736—
RSU9,000$183,150—
RSU3,501$71,245—
Option4,167—$35.61
Option14,000—$60.85
Option12,251—$37.35

Per the Outstanding Equity Awards at Fiscal Year-End table in PUMA BIOTECHNOLOGY, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

PUMA BIOTECHNOLOGY’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Douglas HuntSenior Vice President, Regulatory Affairs, Medical Writing and Project Management$6,754,592
Alan AuerbachPresident and Chief Executive Officer$6,152,550
Maximo NouguesChief Financial Officer$2,281,642
Steven LoChief Commercial Officer$2,236,276
MBChB Richard P. BryceSenior Vice President, Clinical Research and Development$1,893,811
Charles Eyler · this pageSenior Vice President, Finance and Administration$1,836,193

The full PUMA BIOTECHNOLOGY compensation record

free company brief

This page is one person within PUMA BIOTECHNOLOGY's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the PUMA BIOTECHNOLOGY proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PUMA BIOTECHNOLOGY's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Eyler's compensation dossier · One-time report. No refunds.